Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes

Genes and Immunity

Volumn 7, Issue 7, 2006, Pages 544-549

  Zhernakova, A ^a   Alizadeh, B Z ^a   Eerligh, P ^b   Hanifi Moghaddam, P ^b,c   Schloot, N C ^c   Diosdado, B ^a   Wijmenga, C ^a   Roep, B O ^b   Koeleman, B P C ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; RANTES;

ADOLESCENT; ANALYSIS OF VARIANCE; ARTICLE; AUTOIMMUNE DISEASE; CASE CONTROL STUDY; CELIAC DISEASE; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CARRIER; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENE LOCATION; GENE TRANSFER; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; CELIAC DISEASE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; GENE FREQUENCY; HAPLOTYPES; HUMANS; INFANT; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RANTES; VARIATION (GENETICS);

EID: 33750365601     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364326     Document Type: Article

References (44)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-229.
2. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G et al. Association of the T-cell regulatory gene CTLA4 with. susceptibility to autoimmune disease. Nature 2003; 423: 506-511.
3. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36: 337-338.
4. Kelly MA, Rayner ML, Mijovic CH, Barnett AH. Molecular aspects of type 1 diabetes. Mol Pathol 2003; 56: 1-10.
5. Hizawa N, Yamaguchi E, Konno S, Tanino Y, Jinushi E, Nishimura M. A functional polymorphism in the RANTES gene promoter is associated with the development of late-onset asthma. Am J Respir Crit Care Med 2002; 166: 686-690.
6. Al-Abdulhadi SA, Helms PJ, Main M, Smith O, Christie G. Preferential transmission and association of the -403 G→A promoter RANTES polymorphism with atopic asthma. Genes Immun 2005; 6: 24-30.
7. Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, Plunkett BS et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. I Immunol 2000; 164: 1612-1616.
8. Takada T, Suzuki E, Ishida T, Moriyama H, Ooi H, Hasegawa T et al. Polymorphism RANTES chemokine promoter affects extent of sarcoidosis in a Japanese population. Tissue Antigens 2001; 58: 293-298.
9. Leung TF, Tang NL, Lam CW, Li AM, Fung SL, Chan IH et al. RANTES, G-401A polymorphism is associated with allergen sensitization and FEV1 in Chinese children. Respir Med 2005; 99: 216-219.
10. Kozma GT, Falus A, Bojszko A, Krikovszky D, Szabo T, Nagy A et al. Lack of association between atopic eczema/dermatitis syndrome and polymorphisms in the promoter region of RANTES and regulatory region of MCP-1. Allergy 2002; 57: 160-163.
11. Makki RF, al Sharif F, Gonzalez-Gay MA, Garcia-Porrua C, Ollier WE, Hajeer AH. RANTES gene polymorphism in polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis. Clin Exp Rheumatol 2000; 18: 391-393.
12. Gade-Andavolu R, Comings DE, MacMurray J, Vuthoori RK, Tourtellotte WW, Nagra RM et al. RANTES: A genetic risk marker for multiple sclerosis. Mult Scler 2004; 10: 536-539.
13. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445.
14. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108-115.
15. Taub DD, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ. Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro. J Immunol 1996; 156: 2095-2103.
16. Bacon KB, Premack BA, Gardner P, Schall TJ. Activation of dual T cell signaling pathways by the chemokineRANTES. Science 1995; 269: 1727-1730.
17. Wong MM, Fish EN. Chemokines: Attractive mediators of the immune response. Semin Immunol 2003; 15: 5-14.
18. Zou W, Borvak J, Marches F, Wei S, Galanaud P, Emilie D et al. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. J Immunol 2000; 165: 4388-4396.
19. Frauenschuh A, DeVico AL, Lim SP, Gallo RC, Garzino-Demo A. Differential polarization of immune responses by co-administration of antigens with chemokines. Vaccine 2004; 23: 546-554.
20. Makino Y, Cook DN, Smithies O, Hwang OY, Neilson EG, Turka LA et al. Impaired T cell function in RANTES-deficient mice. Clin Immunol 2002; 102: 302-309.
21. Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA 1999; 96: 4581-4585.
22. An P, Nelson GW, Wang L, Donfield S, Goedert JJ, Phair J et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci USA 2002; 99: 10002-10007.
23. The International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789-796.
24. Rodriguez-Frade JM, Vila-Coro AJ, Martin A, Nieto M, Sanchez-Madrid F, Proudfoot AE et al. Similarities and differences in RANTES- and (AOP)-RANTES-triggered signals: Implications for chemotaxis. J Cell Biol 1999; 144: 755-765.
25. Wong M, Uddin S, Majchrzak B, Huynh T, Proudfoot AE, Platanias LC et al. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J Biol Chem 2001; 276: 11427-11431.
26. Cetkovic-Cvrlje M, Dragt AL, Vassilev A, Liu XP, Uckun FM. Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. Clin Immunol 2003; 106: 213-225.
27. Kondoh K, Torii S, Nishida E. Control of MAP kinase signaling to the nucleus. Chromosoma 2005; 114 (2): 86-91.
28. Brill A, Hershkoviz R, Vaday GG, Chowers Y, Lider O. Augmentation of RANTES-induced extracellular signal-regulated kinase mediated signaling and T cell adhesion by elastase-treated fibronectin. J Immunol 2001; 166: 7121-7127.
29. Ando H, Kurita S, Takamura T. The specific p38 mitogen-activated protein kinase pathway inhibitor FR167653 keeps insulitis benign in nonobese diabetic mice. Life Sci 2004; 74: 1817-1827.
30. Eriksson C, Eneslatt K, Ivanoff J, Rantapaa-Dahlqvist S, Sundqvist KG. Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus. Lupus 2003; 12: 766-774.
31. Pierer M, Rethage J, Seibl R, Lauener R, Brentano F, Wagner U et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 2004; 172: 1256-1265.
32. Oki M, Ohtani H, Kinouchi Y, Sato E, Nakamura S, Matsumoto T et al. Accumulation of CCR5+ T cells around RANTES+ granulomas in Crohn's disease: A pivotal site of Th1-shifted immune response? Lab Invest 2005; 85: 137-145.
33. Yang B, Houlberg K, Millward A, Demaine A. Polymorphisms of chemokine and chemokine receptor genes in Type 1 diabetes mellitus and its complications. Cytokine 2004; 26: 114-121.
34. Buhler MM, Craig M, Donaghue KC, Badhwar P, Willis J, Manolios N et al. CCR5 genotyping in an Australian and New Zealand type 1 diabetes cohort. Autoimmunity 2002; 35: 457-461.
35. Masuko-Hongo K, Sato T, Nishioka. K. Chemokines differentially induce matrix metalloproteinase-3 and prostaglandin E2 in human articular chondrocytes. Clin Exp Rheumatol 2005; 23: 57-62.
36. Locati M, Deuschle U, Massardi ML, Martinez FO, Sironi M, Sozzani S et al. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J Immunol 2002; 168: 3557-3562.
37. Garcia-Vicuna R, Gomez-Gaviro, MV, Dominguez-Luis MJ, Pec MK, Gonzalez-Alvaro I, Alvaro-Gracia JM et al. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum 2004; 50: 3866-3877.
38. Schipper RF, Koeleman BP, Bruining GJ, Schreuder GM, Verduijn W, De Vries RR et al. HLA class II associations with type 1 diabetes mellitus: a multivariate approach. Tissue Antigens 2001; 57: 144-150.
39. Hanifi-Moghaddam P, Schloot NC, Kappler S, Seissler J, Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 2003; 52: 1137-1142.
40. Revised Criteria for Diagnosis of Coeliac Disease. Report of working group of European Society of Paediatric Gastroenterology and Nutrition. Arch Dis Child 1990; 65: 909-911.
41. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
42. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
43. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003; 25: 115-121.
44. Haldane JB. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet 1956; 20: 309-311.